All the news Showing 10 of 182 articles from: Hepatitis BGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Simplified tenofovir regimen as effective as recommended preventive treatment in pregnant women with hepatitis B Keith Alcorn / 14 November 2022 A simplified regimen for the prevention of mother-to-child transmission of hepatitis B was just as effective as the standard preventive regimen in pregnant women with very high virus levels and is likely ... VIR-2218 combined with monoclonal antibody or pegylated interferon delivers potent suppression of hepatitis B Keith Alcorn / 14 November 2022 The experimental hepatitis B antiviral VIR-2218 shows potent activity against the virus when combined with either a monoclonal antibody that targets three steps in the hepatitis B lifecycle, or pegylated interferon, two studies ... Bepirovirsen treatment leads to sustained loss of hepatitis B markers for up to one in five Keith Alcorn / 14 November 2022 Up to one in five people with hepatitis B treated with the experimental antiviral bepirovirsen achieved a sustained loss of hepatitis B surface antigen (HBsAg) and HBV DNA, a sign indicating the ... Biktarvy combination pill may be most effective option for people with HIV and hepatitis B Liz Highleyman / 03 August 2022 Although two antiretroviral drug regimens proved about equally effective at suppressing HIV, the Biktarvy combination pill (bictegravir, emtricitabine and tenofovir alafenamide) did a better job suppressing hepatitis B virus (HBV) ... Bepirovirsen suppresses hepatitis B surface antigen, moves forward to larger functional cure studies Keith Alcorn / 29 June 2022 Bepirovirsen, an experimental drug with a novel mode of action, suppressed hepatitis B surface antigen below the limits of detection in approximately 30% of patients after 24 weeks of treatment and ... Bulevirtide leads to sustained improvement for people with hepatitis D Liz Highleyman / 28 June 2022 The entry inhibitor bulevirtide (Hepcludex) led to a reduction in hepatitis delta virus (HDV) viral load, lower liver enzyme levels and improvement in fibrosis after 48 weeks of follow-up, according to findings ... Experimental hepatitis B combination suppresses key marker but fails to achieve functional cure Keith Alcorn / 27 June 2022 People with hepatitis B who received a combination of experimental drugs as well as their standard treatment for 48 weeks were significantly less likely to have high levels of hepatitis B surface ... Depression, anxiety, cognitive performance improve after hepatitis C cure Keith Alcorn / 18 March 2022 Depression, anxiety and cognitive performance each improved significantly in people cured of hepatitis C, Indian researchers report in the Journal of Viral Hepatitis. Anxiety and depression are frequently reported by people with hepatitis C ... Immunoglobulin-free strategy highly effective for prevention of mother-to-child hepatitis B transmission in Cambodia Keith Alcorn / 22 February 2022 A hepatitis B immunuglobulin-free strategy for prevention of mother-to-child hepatitis B transmission is feasible and highly effective in a resource-limited setting if tenofovir is given for at least four weeks prior to delivery, ... Antihistamine use halved the risk of liver cancer in people with viral hepatitis Keith Alcorn / 08 February 2022 Antihistamines used for relief of allergies and hay fever halved the risk of developing hepatocellular carcinoma (HCC; liver cancer) in people with viral hepatitis during a ten-year follow-up period, a review of ... ← First12345...19Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Transmission and prevention Diagnosis and monitoring Disease course and symptoms Treatment HIV and HBV HCV and HBV Hepatitis delta Living with HBV Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive